Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.

Sadikot SM, Mogensen CE.

Diabetes Res Clin Pract. 2008 Dec;82(3):391-5. doi: 10.1016/j.diabres.2008.09.004. Epub 2008 Oct 21.

PMID:
18945509
2.

Sulphonylureas and cancer: a case-control study.

Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E.

Acta Diabetol. 2009 Dec;46(4):279-84. doi: 10.1007/s00592-008-0083-2. Epub 2008 Dec 10.

PMID:
19082520
3.

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Obes Metab. 2012 Sep;14(9):803-9. doi: 10.1111/j.1463-1326.2012.01604.x. Epub 2012 Apr 29.

PMID:
22486923
4.

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):373-9. Epub 2007 Oct 24.

PMID:
17919894
6.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
7.

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.

Khalangot M, Tronko M, Kravchenko V, Kovtun V.

Diabetes Res Clin Pract. 2009 Dec;86(3):247-53. doi: 10.1016/j.diabres.2009.09.008. Epub 2009 Sep 30.

PMID:
19796836
8.

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

Gulliford M, Latinovic R.

Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.

PMID:
15133756
9.

The role of sulphonylureas in the management of type 2 diabetes mellitus.

Rendell M.

Drugs. 2004;64(12):1339-58. Review.

PMID:
15200348
10.

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.

Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:16-24. doi: 10.1111/j.1463-1326.2008.00883.x.

PMID:
18435670
11.

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Care. 2010 Jun;33(6):1224-9. doi: 10.2337/dc10-0017. Epub 2010 Mar 9.

12.
13.

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.

Sillars B, Davis WA, Hirsch IB, Davis TM.

Diabetes Obes Metab. 2010 Sep;12(9):757-65. doi: 10.1111/j.1463-1326.2010.01230.x.

PMID:
20649627
14.

Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.

Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, Boyko EJ.

Diabetologia. 2013 Sep;56(9):1934-43. doi: 10.1007/s00125-013-2958-1. Epub 2013 Jun 25.

PMID:
23797633
15.

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.

Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R, Mérie C, Olesen JB, Weeke P, Schmiegelow M, Norgaard ML, Køber L, Torp-Pedersen C.

Diabetes Res Clin Pract. 2011 Oct;94(1):119-25. doi: 10.1016/j.diabres.2011.07.011. Epub 2011 Aug 9.

PMID:
21831467
16.

Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.

Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert JM, Qiu W, Simpson SH.

Diabetes Obes Metab. 2014 Jan;16(1):22-9. doi: 10.1111/dom.12173. Epub 2013 Jul 19.

PMID:
23802997
17.
18.

Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.

Juurlink DN, Gomes T, Shah BR, Mamdani MM.

Diabet Med. 2012 Dec;29(12):1524-8. doi: 10.1111/j.1464-5491.2012.03772.x.

PMID:
22913620
19.

Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.

Tirkkonen T, Heikkilä P, Huupponen R, Laine K.

J Intern Med. 2010 Oct;268(4):359-66. doi: 10.1111/j.1365-2796.2010.02257.x.

20.

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C.

Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6. Erratum in: Eur Heart J. 2012 May;33(10):1183.

PMID:
21471135

Supplemental Content

Support Center